Crossing over to drug resistance

David M. Livingston and Daniel P. Silver
Additional contact information
David M. Livingston: David M. Livingston and Daniel P. Silver are at the Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA. david_livingston@dfci.harvard.edu daniel_silver@dfci.harvard.edu
Daniel P. Silver: David M. Livingston and Daniel P. Silver are at the Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA. david_livingston@dfci.harvard.edu daniel_silver@dfci.harvard.edu

Nature, 2008, vol. 451, issue 7182, 1066-1067

Abstract: Certain cancers stem from mutations that prevent a cell from repairing its damaged DNA efficiently. But antitumour chemotherapy that exploits that repair defect can in turn be nullified by counter-mutation.

Date: 2008
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/4511066a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:451:y:2008:i:7182:d:10.1038_4511066a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/4511066a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().